Cargando…
Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy
Toll-like receptor 3 (TLR3), as an important pattern recognition receptor (PRR), dominates the innate and adaptive immunity regulating many acute and chronic inflammatory diseases. Atherosclerosis is proved as an inflammatory disease, and inflammatory events involved in the entire process of initiat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513496/ https://www.ncbi.nlm.nih.gov/pubmed/36176917 http://dx.doi.org/10.1016/j.apsb.2022.06.001 |
_version_ | 1784798077508386816 |
---|---|
author | Cen, Xiaohong Wang, Baoqu Liang, Yuqing Chen, Yanlin Xiao, Yu Du, Shaohua Nandakumar, Kutty Selva Yin, Hang Liu, Shuwen Cheng, Kui |
author_facet | Cen, Xiaohong Wang, Baoqu Liang, Yuqing Chen, Yanlin Xiao, Yu Du, Shaohua Nandakumar, Kutty Selva Yin, Hang Liu, Shuwen Cheng, Kui |
author_sort | Cen, Xiaohong |
collection | PubMed |
description | Toll-like receptor 3 (TLR3), as an important pattern recognition receptor (PRR), dominates the innate and adaptive immunity regulating many acute and chronic inflammatory diseases. Atherosclerosis is proved as an inflammatory disease, and inflammatory events involved in the entire process of initiation and deterioration. However, the contribution of TLR3 to atherosclerosis remains unclear. Herein, we identified the clinical relevance of TLR3 upregulation and disease processes in human atherosclerosis. Besides, activation of TLR3 also directly led to significant expression of atherogenic chemokines and adhesion molecules. Conversely, silencing TLR3 inhibited the uptake of oxLDL by macrophages and significantly reduced foam cell formation. Given the aberrance in TLR3 functions on atherosclerosis progression, we hypothesized that TLR3 could serve as novel target for clinical atherosclerosis therapy. Therefore, we developed the novel ellipticine derivative SMU-CX24, which specifically inhibited TLR3 (IC(50) = 18.87 ± 2.21 nmol/L). In vivo, atherosclerotic burden was alleviated in Western diet fed ApoE(−/−) mice in response to SMU-CX24 treatment, accompanying notable reductions in TLR3 expression and inflammation infiltration within atherosclerotic lesion. Thus, for the first time, we revealed that pharmacological downregulation of TLR3 with specific inhibitor regenerated inflammatory environment to counteract atherosclerosis progression, thereby proposing a new strategy and probe for atherosclerosis therapy. |
format | Online Article Text |
id | pubmed-9513496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95134962022-09-28 Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy Cen, Xiaohong Wang, Baoqu Liang, Yuqing Chen, Yanlin Xiao, Yu Du, Shaohua Nandakumar, Kutty Selva Yin, Hang Liu, Shuwen Cheng, Kui Acta Pharm Sin B Original Article Toll-like receptor 3 (TLR3), as an important pattern recognition receptor (PRR), dominates the innate and adaptive immunity regulating many acute and chronic inflammatory diseases. Atherosclerosis is proved as an inflammatory disease, and inflammatory events involved in the entire process of initiation and deterioration. However, the contribution of TLR3 to atherosclerosis remains unclear. Herein, we identified the clinical relevance of TLR3 upregulation and disease processes in human atherosclerosis. Besides, activation of TLR3 also directly led to significant expression of atherogenic chemokines and adhesion molecules. Conversely, silencing TLR3 inhibited the uptake of oxLDL by macrophages and significantly reduced foam cell formation. Given the aberrance in TLR3 functions on atherosclerosis progression, we hypothesized that TLR3 could serve as novel target for clinical atherosclerosis therapy. Therefore, we developed the novel ellipticine derivative SMU-CX24, which specifically inhibited TLR3 (IC(50) = 18.87 ± 2.21 nmol/L). In vivo, atherosclerotic burden was alleviated in Western diet fed ApoE(−/−) mice in response to SMU-CX24 treatment, accompanying notable reductions in TLR3 expression and inflammation infiltration within atherosclerotic lesion. Thus, for the first time, we revealed that pharmacological downregulation of TLR3 with specific inhibitor regenerated inflammatory environment to counteract atherosclerosis progression, thereby proposing a new strategy and probe for atherosclerosis therapy. Elsevier 2022-09 2022-06-09 /pmc/articles/PMC9513496/ /pubmed/36176917 http://dx.doi.org/10.1016/j.apsb.2022.06.001 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Cen, Xiaohong Wang, Baoqu Liang, Yuqing Chen, Yanlin Xiao, Yu Du, Shaohua Nandakumar, Kutty Selva Yin, Hang Liu, Shuwen Cheng, Kui Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
title | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
title_full | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
title_fullStr | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
title_full_unstemmed | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
title_short | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy |
title_sort | small molecule smu-cx24 targeting toll-like receptor 3 counteracts inflammation: a novel approach to atherosclerosis therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513496/ https://www.ncbi.nlm.nih.gov/pubmed/36176917 http://dx.doi.org/10.1016/j.apsb.2022.06.001 |
work_keys_str_mv | AT cenxiaohong smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT wangbaoqu smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT liangyuqing smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT chenyanlin smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT xiaoyu smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT dushaohua smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT nandakumarkuttyselva smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT yinhang smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT liushuwen smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy AT chengkui smallmoleculesmucx24targetingtolllikereceptor3counteractsinflammationanovelapproachtoatherosclerosistherapy |